Abstract Purpose: Activation of the RAS pathway plays a major role in cancer cells. In acute myeloid leukemia (AML), mutations of the RAS genes cause an intrinsic activation of this pathway. Until now, clinical studies could not find clear association of RAS mutations with the clinical outcome after AML therapy. This could be due to alternative initiating events for activation of the RAS pathway like constitutive tyrosine kinase activation or mutations in Ras-regulating genes. Experimental Design: In total,191AML patients (126 as training population and 65 as test population) were studied for Ras activity with a glutathione S-transferase pull-down assay using Raf binding of activated Ras. Results: AML samples showed a wide range of Ras activity values, which was in contrast to normal bone marrow donors who showed no or very limited Ras activity. Using a Ras binding score based on semiquantitative Western blotting, we defined patients with strong Ras activity and compared Ras activity with RAS mutation. Surprisingly, only a minority of RAS mutated AML samples (22.2%) showed strong Ras activity, whereas 25 patients presented strong Ras activity in the absence of RAS mutations. Clinical outcome did not show differences according to RAS mutations. In contrast, Ras activity predicted for a high response rate (P < 0.05) and proved to be an independent factor for overall survival rate (P < 0.05) in younger AML patients receiving high-dose 1-B-D-arabinofuranosylcytosine as induction therapy. Conclusion: The data highlight the role for alternative pathways of Ras activation without RAS mutations. Intrinsically activated Ras seems to increase sensitivity of the AML blast to high-dose 1-B-D-arabinofuranosylcytosine therapy.
Normal function of small G-proteins of the RAS family is a prerequisite of cellular homeostasis. Therefore, activation of Ras proteins is tightly regulated with factors able to activate Ras (guanine-nucleotide exchange factors) or factors able to counteract Ras activation (GTPase activating proteins; for recent review, see ref. 1) .
Activating point mutations of RAS genes have been generally accepted as oncogenic events in the tumorigenesis of a variety malignancies. The mechanisms by which mutant Ras is transforming affected cells have been extensively studied. In general, RAS mutations lead to a resistance of the Ras proteins to signaling provided by GTPase activating proteins thus remaining in the active GTP-bound state (2, 3) . This constitutive activity is furthermore translated via a cascade of key signaling events that contribute to the regulation of proliferation, apoptosis, and differentiation. One example for such a signaling cascade is RAS-GTP recruitment of RAF proteins to the plasma membrane which is activating phosphorylation of mitogenactivated protein kinase (MAPK) kinase and consequently extracellular signal -regulated kinases (ERK). Extracellular signal -regulated kinase activity has been linked to proliferative stimulation and activation of antiapoptotic pathways (4) .
In acute myelogenous leukemia (AML) activating point mutations could be shown to affect almost exclusively N-RAS and K-RAS at codons 12, 13, and 61 (5 -7). These alterations were detected with varying frequencies (25-40%) and resemble one of the most common genetic alterations detected in AML.
The consequences of Ras activity in AML blasts are difficult to predict and may depend on additional genetic alterations. Thus, it is well established that Ras activity may account for an increased proliferation rate and decreased apoptosis rate in experimental systems and there is ample evidence that downstream effectors of Ras, like Erk and Akt readily transmit this signaling. However, under certain conditions, Ras activity may even give rise to increased senescence and proapoptotic signaling (8, 9) . Recently, elegant studies using conditional expression systems of K-Ras clearly showed a growth factor independent proliferative advantage in transformed hematopoietic cells with subsequent development of a myeloproliferative disease in mice (10, 11) .
Given the potential effect of activating point mutations on cellular physiology, one might expect in AML patients an association between RAS mutations and an aggressive course of the disease. However, there may be interactions between genetic alterations (e.g., RAS mutations) and therapeutic modalities. Thus, RAS mutations harbor poor prognosis in lung cancer without adjuvant chemotherapy, whereas in lung cancer or AML, RAS mutations may be associated with better outcome after chemotherapy (6, 12) , which may be caused by a differential sensitivity of RAS mutated cells towards 1-h-D-arabinofuranosylcytosine (ara-C) containing chemotherapy (13) . However, other studies revealed conflicting data and did not show an independent effect of RAS mutations on therapy outcome (5, 7, 14) .
One potential reason for this inconsistency may be that AML samples with wild-type RAS have acquired activation of Ras by constitutive signals arising from gain-of-function alterations in upstream tyrosine kinases. To date, several models of constitutive Ras activation in AML cell lines have been proposed. It is possible that aberrantly expressed cytokines can activate Ras. Examples for an autocrine stimulatory effect on Ras in AML include constitutive expression of basic fibroblast growth factor and vascular endothelial growth factor (15, 16) . Additionally, signaling molecules that interact with Ras activation may interfere with normal GTPase activity of the cell, as it is the case for neurofibromin (17) , or activate Ras by aberrantly amplifying signals from other growth factor receptors associated molecules, like the PTPN11-encoded phosphatase SHP-2 (18) . Finally, FLT-3 internal tandem duplications (ITD), the most common type of genetic alteration in standard risk AML patients, was shown to exert transforming potential via the Ras pathway (19) .
Considering this, the state of activity of Ras may shed more light on clinical consequences of the Ras pathway compared with mutational analysis of the RAS gene. Therefore, we initiated a study highlighting the importance of Ras activity in a large homogeneously treated AML patient population.
Materials and Methods
Patient blast samples/cell lines. In total, 191 previously untreated AML patients were studied. Patients with the diagnosis AML FrenchAmerican-British subtype M3 were excluded and treated in a separate trial. Blast samples were obtained from each patient at the time point of diagnosis. Mononuclear cells were prepared by a standardized ficol procedure and cryopreserved in vials containing 5 to 20 Â 10 6 cells. Additionally, nine bone marrow samples of healthy donors were acquired at the time point of donation. Mononuclear cells were prepared and cryopreserved exactly as it is described for AML blast samples. All patients and healthy donors gave written informed consent for the use of their samples.
HeLa cells served as control in the precipitation assay for Ras activity. Cells were obtained by the German Collection of Microorganism and Cell Cultures (Braunschweig, Germany). The cell line was grown in RPMI 1640 supplemented with 1% penicillin, streptomycin, 10% FCS, and 1% nonessential amino acids under standard conditions. Twelve hours before stimulation, experiment cells were grown in starving medium (containing 0.5% FCS). Thereafter, cells were stimulated with epidermal growth factor (50 ng/mL) for 5 minutes.
Treatment characteristics. The study of the SHG96 study group is using two different induction treatment schedules (14) . Younger patients (V60 years) received a double-induction treatment, of which the second regimen contained intermediate dose ara-C (10 g/m 2 ). Postremission therapy is priority based and risk adapted, including chemotherapy for AML good risk patients, allogeneic transplantation with related donors, autologous or chemotherapy for patients with high risk, and allogeneic transplantation with the option of unrelated donors, autologous, or chemotherapy for patients with high risk. Patients ages >60 years were treated with low-dose ara-C. Postremission therapy in older patients was individualized with the option of intermediate dose ara-C application. Cytogenetic stratification was done only in patients ages <60 years, because older patients were not treated in a risk-adapted fashion.
Cytogenetic risk groups were defined as follows: high risk: À5/ del(5q), À7/del(7q), hypodiploid karyotypes (besides 45,X,ÀY or ÀX), inv(3q), abnl12p, abnl11q, +11, +13, +21, +22, t(6;9); t(9;22); t(9;11); t(3;3), multiple aberrations; intermediate risk: patients without low-risk or high-risk constellation; low risk: t(8;21) and t(8;21) combined with other aberrations. AML patients with inv16 were considered intermediate risk.
Complete remission (CR) was defined as the presence of <5% of blast cells in a standardized bone marrow puncture after the second course of induction therapy. Only patients with fully regenerated blood counts were considered in CR. The study was approved by the ethics committee of the University of Dresden (review no. EK210396).
Precipitation of activated RAS (glutathione S-transferase pull-down assay). Ras precipitation probes were analyzed in two different cohorts from two independent investigators (S.S. and A.F.). The training set included 126 patient samples; the test set included 65 samples (n = 191). For the first cohort of patients (n = 126), genomic DNA was available for PCR-based techniques. Therefore, all analyses regarding RAS mutations refer to 126 patients.
Samples to be analyzed were chosen by the percentage of blasts determined at the time point of diagnosis. Thus, we decided to analyze exclusively blast samples with a blast percentage >50% at the time point of diagnosis (in either pB or bone marrow). After identification of these samples, vials were thawed. To exclude samples with low viability, samples were stained with trypan blue. Specimens with a viability <50% were excluded from the analysis. Both stimulated HeLa cells (2 Â 10 7 ) and blast samples (1-2 Â 10 7 ) with a sufficient blast count and viability were washed twice in ice-cold PBS. After centrifugation at 1,800 rpm at 4jC, cells were immediately referred to ice-cold MLB lysis buffer (600-800 AL; 25 mmol/L HEPES, 150 mmol/L NaCl, 10% glycerol, 1% Igepal, 0.25% SDS, 10 mmol/L MgCl 2 , 1 mmol/L EDTA, 1 mmol/L sodiumorthovanadate, 25 mmol/L sodium fluoride, 10 Ag/mL leupeptin, and 10 Ag/mL aprotinin). The solution was vigorously shaken at 4jC for 30 minutes. Thereafter, cellular debris was pelleted by centrifugation with 14,000 rpm at 4jC and 500 AL of the samples were immediately quick frozen at À80jC. Proteins were quantitated using the bicinchoninic acid protein assay (Pierce, Rockford, IL). Protein (30 Ag) was resolved by 12% SDS-PAGE, transferred to Hybond enhanced chemiluminescence nitrocellulose membrane (Amersham Pharmacia Biotech, Freiburg, Germany) and immunoblotted with the primary antibody detecting human actin (Sigma-Aldrich, Mü nchen, Germany; 1:1,000 at 4jC, overnight). The antigen was detected with a horseradish peroxidase -coated secondary mouse antibody (1:2,500 at room temperature, 1 hour) and enhanced chemiluminescence reagent (Amersham Pharmacia Biotech). Blots were controlled by immunostaining of actin (see Fig. 1 ). Only probes revealing nondisintegrated actin immunosignals were chosen for further evaluation by the RAF-based precipitation method.
Thereafter, protein samples were thawed and sample volumes were adjusted to 1 mL containing 500 Ag of protein. Next, samples were precleared with 20 AL glutathionagarose (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes at 4jC. After centrifugation at 14,000 rpm at 4jC supernatants were used for glutathione S-transferase (GST) pull-down with 10 AL of a GST-tagged fusion protein corresponding to residues 1-149 of the human Ras binding domain of RAF-1 (Upstate Biotechnology, Waltham, MA). Samples were incubated at 4jC for 30 minutes. After centrifugation and three times washing in MLB buffer, the pellets were dissolved in Western probe buffer and heated at 95jC for 5 minutes. Supernatants were used for Western blotting using primary antibodies detecting precipitated RAS (Upstate Biotechnology; 1:1,000, at 4jC, overnight). The antigen was detected with a horseradish peroxidase -coated secondary mouse antibody (1:2,500 at room temperature, 1 hour) and enhanced chemiluminescence reagent (Amersham Pharmacia Biotech). Moreover, the same blots were immunostained with primary antibodies detecting GST (Santa Cruz Biotechnology) to assure equal loading of the precipitate. Again, the antigen was detected with a horseradish peroxidase -coated secondary mouse antibody (1:2,500 at room temperature, 1 hour) and enhanced chemiluminescence reagent (Amersham Pharmacia Biotech).
Immunoblotted signals were scanned with a Biometra device and analyzed with ScanPack3 software (Biometra, Gö ttingen, Germany). Relative amounts of activated Ras were calculated using a ratio of the obtained absorbance values for Ras*/Ras antigen (Fig. 1B) . Because a broad range of Ras activity values was determined, we decided to define a threshold which was further used to describe Ras activity -positive versus Ras activity -negative samples. The threshold was defined as the 75% percentile of the observed range of activity. In the training group (n = 126), this threshold was therefore set 1%. In the test set (n = 65), we were able to increase the sensitivity of the assay and detected a differing threshold (45%).
Detection of N-RAS/K-RAS point mutations. Genomic DNA was extracted from 5 Â 10 6 cells using either phenol/chloroform extraction after proteinase K digestion or a silica based procedure (Qiagen DNA Blood Kit, Qiagen, Hilden, Germany) according to the manufacturer's protocols.
N-RAS mutations were determined as previously described using a denaturing heteroduplex high-pressure liquid chromatographybased method (20) . In brief, primer pairs were as follows: N12/13 assay, forward 5V -GACTGAGTACAAACTGGTGG-3V and reverse, 5V -TGCATAACTGAATGTATACCC-3V ; N61 assay, forward 5V -CAAGTGGTTA-TAGATGGTGAAACC-3Vand reverse, 5V -AAGATCATCCTTTCAGAGAAAA-TAAT-3V . PCR conditions were for exon 1, Hot Star Taq (Qiagen, Valencia, CA), 0.625 unit primers (12.5 pmol), N12/13 forward, N12/13 reverse. Denaturing, 95jC for 15 minutes and 94jC for 30 seconds; annealing, 55.5jC for 1 minute; extension, 72jC for 1 minute for 35 cycles; final cycle at 72jC for 10 minutes and for exon 2, Hot Star Taq (Qiagen, Valencia, CA), 0.625 unit primers (12.5 pmol), N61F forward, N61R reverse. Denaturing, 95jC for 15 minutes; 94jC for 30 seconds; annealing, 55.5jC for 1 minute; extension, 72jC for 1 minute for 35 cycles; final cycle at 72jC for 10 minutes. Heteroduplexes were generated by means of a thermal cycler as follows: 95jC for 5 minutes; 95jC, reducing at 1jC per 22 seconds, for 70 cycles. Then, 10 L heteroduplexed PCR product per well were loaded from 96-well plates and analyzed by heteroduplex high-pressure liquid chromatography under the following conditions: flow, 0.9 mL/min, 47% to 52% buffer (B) in 0.1 minute, to 60% B in 4 minutes at 61jC.
K-RAS (codon 12) mutations were detected with a RFLP PCR method essentially as it was described previously (21) . The sequences of primers were P1 5V-CTTGTGGTAGTTGGACCT-3V , P2 5V -GTCAGAGAAACCTT-TATCTG-3V , and P3 5V-TGCACCAGTAATATGCATAT-3V. The primers for the first PCR were P1 (sense) and P2 (antisense) that flanked codon 12 of the K-RAS gene. After the first PCR amplification, the PCR product was digested with 1 AL (10 units/mL) of MvaI at 37jC for 1 hour. Subsequently, 5 AL of the reaction mixture were subjected to a second round of PCR and amplified for 30 cycles under the same conditions using primers, sense P1 and antisense P3. The second PCR products were also digested with 1 AL (10 units/mL) of MvaI for 1 hour. Mutational screening was done by agarose gel electrophoresis.
All aberrant PCR fragments corresponding to a potential mutation in N-RAS as detected by heteroduplex high-pressure liquid chromatography or K-RAS as detected by RFLP-PCR were subjected to direct sequencing.
Detection of FLT-3 ITD mutations was exclusively done as previously reported (22 
regression analysis using multiple variables was done to identify the effect of single variables on CR. Cox regression analysis was used to identify independent variables associated with overall survival and disease-free survival. Estimates of overall survival and disease-free survival were calculated by the method of Kaplan and Meyer. Rates of overall survival were compared using the log rank test. All Ps are two sided and a significance level of 0.05 was used. All analyses were done using SPSS software.
Results

RAS mutations in AML.
Previous studies in AML patients reported that RAS mutations are mainly found in N-RAS 12, N-RAS 13, N-RAS 61, and K-RAS 12 with only incidental cases with K-RAS 13 and K-RAS 61 mutations. Therefore, we focused on the investigation of N-RAS 12, N-RAS 13, N-RAS 61, and K-RAS 12. In total, 27 of 126 (21.4%) patients studied had mutations in N-RAS and/or K-RAS genes. In detail, we detected 12 mutations at the N-RAS 12 locus, two mutations at N-RAS 13, four mutations at N-RAS 61, and 12 mutations at K-RAS 12. Among these mutations, three patients were affected by a double mutation at N-RAS12 + N-RAS 13 (one patient), N-RAS 12 + K-RAS 12 (one patient), and one mutation at N-RAS 61 + K-RAS 12 (one patient). All identified mutations led to an amino acid change in the corresponding Ras protein.
Clinical characteristics in RAS mutated versus nonmutated AML patients are shown in Table 1 . There were no significant differences in age, FAB, or cytogenetic risk groups regarding the investigated RAS mutation distribution. In contrast, we observed significantly more patients with prior MDS and secondary AML that were shown to have mutations in N-RAS/ K-RAS, respectively ( Table 1) . As it was previously published, there is a negative correlation between the occurrence of RAS mutations and the presence of FLT-3 ITD mutations in the investigated patient samples.
Ras activation and clinical characteristics in acute myeloid leukemia patients. In the first step, Ras activity of nine healthy bone marrow donors was determined by the RAF-GST pulldown assay. As it is shown in Fig. 1A , Ras activity of healthy bone marrow donor samples was very low or undetectable (Fig. 1A) . The ratio Ras*/Ras varied substantially between AML patients. Therefore, a cutoff was defined for the individual cohort of patients investigated in the GST pull-down assay describing Ras activity -positive versus Ras activity -negative samples (see Materials and Methods and Fig. 1B) . Characteristics of Ras activity -positive versus Ras activity -negative patients are listed in Table 2 . There were no significant differences in clinical or laboratory characteristics in the investigated patients. This investigation holds also true for the analysis of blast percentage in Ras-positive versus Ras-negative samples indicating that Ras activity is not simply affected by the amount of leukemic cells in the investigated patients.
Next, we investigated the relationship between RAS mutational status of the AML samples and Ras activity status (Table 3) . Using the described threshold for Ras activity definition, most patients were defined as RAS mutation and Ras activity negative. Surprisingly, 77.7% of patients with a RAS mutation were classified as Ras activity negative cases. In contrast, 25% of patients without RAS mutations were shown to have strong Ras activity.
Treatment characteristics of RAS-mutated and Ras-activated acute myeloid leukemia patients. RAS mutations were not associated with treatment response criteria (see Table 4 ). In contrast, univariate analysis showed that patients with strong Ras activity were more likely to achieve CR compared with their Ras activity -negative counterparts (CR in Ras activity -positive versus Ras activity -negative patients, 64.5% versus 46.3%). This association was strongest in younger patients receiving high-dose ara-C during the induction therapy (89.5% versus 55.6%, P < 0.05), whereas older patients with strong Ras activity and low-dose ara-C treatment were not affected by the Ras activity score (data not shown).
Moreover, strong Ras activity accounted for an increased overall survival rate again mainly in patients under the age of 61. Disease-free survival and probability of relapse were not affected by the Ras activity score in the initially investigated 126 patients (data not shown).
To further substantiate data on clinical outcome according to the Ras activity score, another 65 patients were investigated as test set. We used the same criteria to define Ras activity in these subsequent 65 patients (>75% percentile of the distribution of Ras*/Ras). As it was detected for the training set of 126 patients, there were no associations to clinical or laboratory characteristics in these 65 additionally investigated patients (FAB, leukocyte count, bone marrow blasts, status at diagnosis, cytogenetic risk classification, and FLT-3 ITD mutation rate; data not shown). Additionally, therapy outcome was comparable to the initially investigated group of patients with higher CR and overall survival rate affecting mainly patients under the age of 60 (data not shown). Again, there was no effect of Ras activity score on disease-free survival and probability of relapse.
Because both groups had very similar characteristics, we analyzed both patient groups to define variables for treatment response. Univariate analysis of all investigated AML patients (n = 191) did not reveal an independent effect of Ras activity on therapy outcome. CR rate was 59.6% in Ras activity -positive patients versus 47.9% in Ras activity -negative patients (191 analyzed patients; P = 0.2). Median overall survival rate was 16.9 months for Ras activity -positive patients and 9.3 months in the Ras activity -negative counterparts (191 analyzed patients; P = 0.2). In addition, multivariate analysis, including age, cytogenetic risk classification of the SHG96 study, status of the disease, FLT-3 ITD status, and Ras activity score (n = 191), did not reveal an independent effect of Ras activity on therapy outcome.
However, multivariate analysis in younger AML patients (<60 years) did show an independent effect of Ras activity on therapy outcome (Table 5) . Subsequently, univariate analysis showed that CR rate was 82.1% versus 58.3% in Ras activitypositive versus Ras activity -negative patients (112 analyzed patients; P < 0.05). Moreover, median overall survival rate was substantially different (32.5 versus 10.4 months in Ras activitypositive versus Ras activity -negative patients; Fig. 2A ). There was no effect on disease-free survival or RFS (Fig. 2B) .
Finally, we analyzed the effect of RAS activity in the subgroup of patients with FLT-3 ITD. Ras activity seems to overcome some of the bad prognostic properties conferred by FLT-3 mutations with an effect on the overall survival rate in younger patients (<60 years) with FLT-3 mutations (median overall survival, 19.9 versus 5.8 months in Ras activity -positive versus Ras activity -negative patients; P < 0.05; data not shown).
Discussion
Activating point mutations of the RAS genes are among the most common observed genetic alterations in AML patients. It could be shown that these mutations account for phenotypic changes in transformed hematopoietic cells like hyperproliferation, hypersensitivity to growth factor stimulation, and IL-3 -independent colony-forming unit activity (10, 11) . Recently, it was found that other genetic or epigenetic alterations may regulate Ras activity in AML blasts (17, 18) . The current study therefore investigated whether Ras activity is restricted to patients carrying RAS mutations and determined the clinical effect of Ras activity in a large AML study population. RAS mutations were not associated with strong Ras activity because only 22.2% of RAS samples with mutation showed at the same time activation. Not surprisingly, we found that strong Ras activity may arise even in patients without activating point mutations. As there are multiple pathways that positively interact with Ras activity, it is very difficult to ascertain which pathway is activated in the individual patient. However, the clinically most important interaction could be Ras activation by ITD of FLT-3 which has been shown by Mizuki et al. (19) . Our data also show inverse relation between the occurrence of FLT3-ITD and RAS mutations. However, the data presented here do not support the idea that an isolated FLT-3 ITD may lead to a strong Ras activity in AML because only a minority of FLT ITD -positive samples was shown with a strong Ras activity. These data are in accordance with Mizuki et al. who showed only moderate Ras activation after transfection of a constitutively active FLT-3. Moreover, the finding that Ras activity may overcome worse prognosis in younger patients even in the presence of FLT-3 mutations is arguing for an FLT-3 -independent cellular mechanism affecting the sensitivity of cells towards high-dose ara-C.
Birkenkamp et al. investigated 22 AML samples for the presence of Ras activation and mutation and found four RASmutated patient samples with a varying degree of Ras activation (23) . The small number of patient samples investigated did not allow for further conclusions. However, considering our results, it must be asked whether the AML blast has the opportunity to counteract Ras activity that is associated with RAS mutation. Molecules that potentially interfere with the activation of the Ras pathway include members of the Sprouty gene family and the Raf kinase inhibitor RKIP which have been shown to effectively abrogate Ras/Raf/MAPK kinase signaling (24, 25) . However, clinical data in AML patients are missing and further studies have to show an effect of those molecules.
Our results indicate that AML patients with high Ras activity show high sensitivity against cytotoxic treatment compared with the Ras activity -negative counterparts. However, this is true only for AML patients ages <61 years. The occurrence of AML in older patients is associated with the presence of bad risk cytogenetic alterations, p53 mutations, and epigenetic alterations like P-gp/ MDR1 expression that may interfere with a successful treatment approach (7) and Ras activity that readily achieved remission in the current treatment protocol (data not shown), another explanation for the observed differences in treatment outcome seems likely. In the AML-SHG-96 study, younger AML patients received far higher doses of the cytotoxic compound ara-C compared with older patients for induction treatment. Efficacy of ara-C treatment in AML may depend on properties of AML blasts like the expression of ara-C transporters and the activity and expression of important enzymes for ara-C phosphorylation/ dephosphorylation (26) . Another critical property of ara-C efficacy is the proliferative activity in AML blasts. Thus, younger AML patients with high Ras activity may show increased susceptibility towards the application of high-dose ara-C treatment. Given the potential dependence of ara-C efficacy on an activated Ras pathway, even a subgroup of older patients may benefit from a strategy using high-dose ara-C (27) . In contrast, low-dose ara-C as applied in our treatment protocol may not be sufficient to exert its positive effects on cell cycle inhibition and apoptosis in older patients. These notions are supported by previous reports from Koo et al. (13) . The authors found increased sensitivity of ara-C in RAStransformed human kidney epithelial cells. RAS-transformed cells failed to arrest the cell cycle in response to ara-C thereby giving rise to an increased rate of ''intra S-phase apoptosis.'' In this light, the data presented here raise the question whether modulation of growth promoting pathways will be of clinical importance in AML. Results from clinical trials investigating the role of farnesyltransferase inhibitors in AML indicate a potential efficacy of these drugs in single-agent application schedules. In a recently published trial, 30% of patients showed response to the farnesyltransferase inhibitor R115777 (28) . None of the responders presented with RAS mutation; however, Ras activity was not investigated and patients with increased MAPK activity showed a tendency towards better silencing of the RAS/RAF/MAPK kinase pathway, indicating a potential role for Ras activity in drug sensitivity towards farnesyltransferase inhibitors. In contrast, silencing of proliferation by the interaction with the Ras pathway does not seem beneficial for a subsequent chemotherapy using cell cycle active compounds like ara-C. There are now preclinical data showing that inhibition of growth promoting pathways like FLT-3 ITD or MAPK kinase activity may reduce sensitivity of a subsequent treatment with ara-C (29, 30) . Alternatively, only recently, it was published that strong Ras activation may be associated with reduced proliferation and enhanced maturation and differentiation of leukemic cells (31) . Thus, Ras activity in the here-investigated population may also account for a commitment to granulocytic differentiation that is more sensitive to ara-C therapy as highly resistant myeloid precursors.
The data presented here indicate that Ras activity resembles a sensitizing mechanism of blasts to the application of ara-C. Whether these properties are restricted only to patients presenting with an activated Ras pathway at diagnosis or whether these properties can be induced by exogenous stimulation of AML blast and consequently lead to an increased response rate awaits further clinical investigation.
